GSK
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a significant discount to growth-based intrinsic value ($110.92) but a premium to defensive fair value.
- P/E of 14.42 is low for the sector
- PEG of 0.50 is highly bullish
- Current price is well above the Graham Number ($30.62)
Strong YoY growth trajectory outweighs short-term quarterly fluctuations.
- YoY Earnings Growth of 54.70%
- Forward P/E of 10.50 suggests earnings expansion
- Recent Q/Q EPS volatility
Exceptional track record of exceeding analyst expectations over 25 quarters.
- 3/4 beats in last 4 quarters
- Long-term history of positive earnings surprises
Liquidity is the primary weakness; the company relies on continuous cash flow to meet short-term obligations.
- Piotroski F-Score of 4/9 (Stable)
- Current Ratio < 1.0
- Quick Ratio of 0.50
Dividend is well-covered by earnings and provides a steady return floor.
- 3.27% yield
- Conservative payout ratio (46.54%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GSK and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GSK
GSK plc
Primary
|
+77.5% | +69.5% | +48.1% | +25.9% | +0.7% | -5.5% |
|
HCA
HCA Healthcare, Inc.
Peer
|
+225.1% | +111.6% | +37.9% | +22.4% | +12.5% | -0.8% |
|
BMY
Bristol-Myers Squibb Company
Peer
|
+2.8% | -13.4% | -2.9% | +15.8% | +1.1% | -1.1% |
|
MCK
McKesson Corporation
Peer
|
+373.0% | +141.7% | +38.6% | +16.5% | +6.3% | -1.2% |
|
VRTX
Vertex Pharmaceuticals Incorporated
Peer
|
+109.6% | +41.7% | -7.9% | +14.0% | -8.1% | -0.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GSK
GSK plc
|
BULLISH | $108.22B | 14.42 | 43.3% | 17.5% | $54.22 | |
|
HCA
HCA Healthcare, Inc.
|
BULLISH | $108.0B | 18.28 | -% | 8.5% | $472.65 | Compare |
|
BMY
Bristol-Myers Squibb Company
|
NEUTRAL | $111.25B | 18.46 | 33.8% | 12.6% | $54.65 | Compare |
|
MCK
McKesson Corporation
|
BULLISH | $104.45B | 26.32 | -% | 1.0% | $842.09 | Compare |
|
VRTX
Vertex Pharmaceuticals Incorporated
|
NEUTRAL | $113.44B | 28.9 | 22.5% | 32.9% | $446.54 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | Martinez-Davis (Maya) | Purchase | 293 | $17,336 | |
| 2026-04-14 | Martinez-Davis (Maya) | Purchase | 152 | $8,870 | |
| 2026-04-14 | Ramakrishnan (Shobie) | Purchase | 601 | $35,561 | |
| 2026-04-13 | Conrad (D) | Purchase | 11 | $641 | |
| 2026-04-13 | Conrad (D) | Purchase | 65 | $3,792 | |
| 2026-04-09 | Barron (Hal V) | Purchase | 26 | $1,532 | |
| 2026-04-09 | Beal (Anne M.D.) | Purchase | 32 | $1,885 | |
| 2026-04-09 | Anderson (Elizabeth McKee) | Purchase | 26 | $1,532 | |
| 2026-04-09 | Bancroft (Charles A) | Purchase | 313 | $18,445 | |
| 2026-04-09 | Dietz (Hal) | Purchase | 30 | $1,767 | |
| 2026-04-09 | Lee (Jeannie) | Purchase | 14 | $825 | |
| 2026-04-09 | Sikka (Vishal Ph.D.) | Purchase | 96 | $5,657 | |
| 2026-04-07 | Martinez-Davis (Maya) | Purchase | 9 | $502 | |
| 2026-03-30 | Conrad (D) | Purchase | 12 | $653 | |
| 2026-03-24 | Conrad (D) | Purchase | 428 | $22,268 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
GSK submitted its annual 20-F filing on March 3, 2025, providing a comprehensive overview of its yearly financial performance and operational results. The report details the company's financial position and outlines the primary risk factors associated with its global pharmaceutical and healthcare operations.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning GSK from our newsroom.